Skip to the page

Data / Drug companies / Fresenius Medical Care Renal Therapies Group, LLC

Fresenius Medical Care Renal Therapies Group, LLC: 13 products in the FDA NDC directory, labeler code 49230

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Fresenius Medical Care Renal Therapies Group, LLC (labeler code 49230) lists 13 products in the FDA National Drug Code Directory, covering 3 finished drugs by generic name. By type: 13 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on November 27, 2013.

The request: Watch Fresenius Medical Care Renal Therapies Group, LLC (FDA labeler code 49230): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
49230
Products in commercial distribution
13
Packages
37
Finished drugs by generic name
3
Prescription products
13
Over the counter products
0
Flagged as original packager
3 of 3 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
November 30, 1984
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)1292.3%
Generic drugs (ANDA)17.7%

Products by type

TypeProductsShare
Prescription drugs13100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Sucroferric oxyhydroxide21
Iron sucrose25
Sodium chloride171

Dosage forms

Dosage formProductsShare
Solution861.5%
Tablet, chewable215.4%
Injection, solution215.4%
Injection17.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Velphoro49230-646Tablet, chewableNew drug applications (NDA)November 27, 2013
Velphoro49230-645Tablet, chewableNew drug applications (NDA)November 27, 2013
Venofer49230-530Injection, solutionNew drug applications (NDA)January 27, 2011
Venofer49230-534Injection, solutionNew drug applications (NDA)November 4, 2008
Sodium Chloride49230-300InjectionGeneric drugs (ANDA)April 12, 2007
Delflex49230-212SolutionNew drug applications (NDA)August 19, 1992
Delflex49230-212SolutionNew drug applications (NDA)August 19, 1992
Delflex49230-209SolutionNew drug applications (NDA)August 19, 1992
Delflex49230-209SolutionNew drug applications (NDA)August 19, 1992
Delflex49230-206SolutionNew drug applications (NDA)August 19, 1992
Delflex49230-206SolutionNew drug applications (NDA)August 19, 1992
Delflex49230-191SolutionNew drug applications (NDA)November 30, 1984
Delflex49230-188SolutionNew drug applications (NDA)November 30, 1984

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.